Suppr超能文献

阿帕替尼对倍他司汀体内外药代动力学的影响。

The effect of apatinib on pharmacokinetic profile of buspirone both in vivo and in vitro.

机构信息

The Seventh People's Hospital of Wenzhou, Wenzhou, Zhejiang, China.

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.

出版信息

J Pharm Pharmacol. 2020 Oct;72(10):1405-1411. doi: 10.1111/jphp.13320. Epub 2020 Jun 30.

Abstract

OBJECTIVE

In this study, we aimed to investigate the potential interaction of apatinib and buspirone and underlying mechanism.

METHODS

UPLC-MS/MS assay was applied to determine the concentrations of buspirone and its main metabolites (1-PP and 6-OH buspirone) after incubated with liver microsomes. Moreover, the connection of in vitro and in vivo was further determined. Sprague Dawley rats were randomly divided into two groups: group A (20 mg/kg buspirone) and group B (buspirone vs 40 mg/kg apatinib). Tail vein blood was collected and subjected to the UPLC-MS/MS detection.

KEY FINDINGS

Apatinib inhibited the generations of 1-PP and 6-OH buspirone dose-dependently with IC of 1.76 and 2.23 μm in RLMs, and 1.51 and 1.48 μm in HLMs, respectively. There was a mixed mechanism underlying such an inhibition effect. In rat, AUC , AUC , T and C of buspirone and 6-OH buspirone increased significantly while co-administering with apatinib, but V and CL decreased obviously while comparing group A with group B .

CONCLUSIONS

Apatinib suppresses the CYP450 based metabolism of buspirone in a mixed mechanism and boosted the blood exposure of prototype drug and 6-OH buspirone dramatically. Therefore, extra caution should be taken when combining apatinib with buspirone in clinic.

摘要

目的

本研究旨在探讨阿帕替尼与丁螺环酮的相互作用及其潜在机制。

方法

采用 UPLC-MS/MS 法测定肝微粒体孵育后丁螺环酮及其主要代谢物(1-PP 和 6-OH 丁螺环酮)的浓度。此外,还进一步确定了体内外的相关性。将 Sprague Dawley 大鼠随机分为两组:A 组(20 mg/kg 丁螺环酮)和 B 组(丁螺环酮与 40 mg/kg 阿帕替尼)。采集尾静脉血,采用 UPLC-MS/MS 检测。

主要发现

阿帕替尼以浓度依赖性方式抑制 1-PP 和 6-OH 丁螺环酮的生成,在 RLMs 中的 IC 分别为 1.76 和 2.23 μm,在 HLMs 中的 IC 分别为 1.51 和 1.48 μm。这种抑制作用存在混合机制。在大鼠中,与阿帕替尼合用后,丁螺环酮和 6-OH 丁螺环酮的 AUC , AUC, T 和 C 显著增加,而 V 和 CL 明显降低,与 A 组相比,B 组更为明显。

结论

阿帕替尼以混合机制抑制丁螺环酮的 CYP450 相关代谢,并显著增加原型药物和 6-OH 丁螺环酮的血药暴露。因此,在临床联合应用阿帕替尼和丁螺环酮时应格外小心。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验